AI-enabled Stroke Prediction in Patients with Chronic Kidney Disease
AI-enabled Stroke Prediction in Patients with Chronic Kidney Disease
批准号:
10481070
负责人:
Waqaas Al-Siddiq
金额:
$24.01万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-01 至 2023-08-31
关键词:
AdoptedAffectAgeAlgorithmsAmbulatory MonitoringAnticoagulant therapyAortic Valve StenosisArrhythmiaArtificial IntelligenceAtrial FibrillationBlood coagulationBody mass indexBrain hemorrhageBusinessesCardiacCardiovascular DiseasesCaringChronic CareChronic DiseaseChronic Kidney FailureClinicalComputersCustomDataData SetDetectionDevelopmentDevicesDiabetes MellitusDialysis procedureElectrocardiogramEnd stage renal failureEngineeringFDA approvedFeasibility StudiesGeneral PopulationHealthcareHeart DiseasesHeart failureHeightHemorrhageHypertensionInstitutesIschemic StrokeLeadLiquid substanceMachine LearningMeasurementMedical DeviceMonitorNephrologyOutpatientsPathway AnalysisPatientsPatternPhasePopulationPreventionPrevention strategyReal-Time SystemsRiskRisk FactorsRunningSchemeSchoolsSensitivity and SpecificitySignal TransductionSmall Business Innovation Research GrantSpecialistStrokeSystemTechnologyTelemetryTherapeuticTimeTrainingUnited States National Institutes of HealthValidationVariantWeightWeight Gainalgorithm trainingartificial neural networkautomated algorithmbaseclinical practicecommercializationcomorbidityconvolutional neural networkcostdata integritydetection platformexperiencehigh riskinnovationmortalitymultidisciplinaryneural network algorithmpersonalized approachpersonalized therapeuticphase 1 studyportabilitypost strokeprediction algorithmpreventive interventionreal time monitoringremote monitoringrisk predictionrisk stratificationskillsstroke risk
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Chronic Kidney Disease (CKD) affects 14% of the U.S. population and is associated with a high risk of both
ischemic and hemorrhagic strokes and a mortality rate of up to three times that of the general population.
Effective stroke risk prediction is flawed in CKD patients, because 1) comorbidities often remain undiagnosed,
2) stroke risk stratification schemes do not consider stages of CKD, and 3) the detection of stroke risk variations
due to dialysis requires real-time risk monitoring, which is unavailable to date. The real-time monitoring of the
stroke risk in CKD patients, and in particular for those undergoing dialysis, is likely to influence adopted
therapeutic strategies and promote a more personalized therapeutic approach. Better care and prevention
through monitoring of these high-risk patients will reduce mortality rates and their high per capita cost, which is
five times higher than the average healthcare spending. Biotricity is developing Bioflux-AI, an innovative system
for real-time monitoring and prediction of stroke episodes in CKD patients. Bioflux-AI combines an
FDA-approved, high-precision, small mobile cardiac telemetry (MCT) device with AI-driven algorithms
specifically trained for the prediction of stroke in stage 4 and 5 CKD patients. Biotricity has previously generated
and validated algorithms for the automated detection of ECG abnormalities, including Atrial Fibrillation (AF).
Given the strong association of AF with increased risk of blood clot formation and hence, ischemic stroke in CKD
patients, Biotricity proposes to combine the detection of this arrhythmia with other stroke risk factors of CKD
patients (age, weight, height, BMI, CKD status, diabetes, heart disease) and ECG parameters to predict stroke
risk in real-time. To this aim, in this SBIR Phase I project a convolutional neural network algorithm, which will
incorporate all these risk factors, will be developed, trained and validated. The accomplishment of this feasibility
study will pave the road for further development and optimization of the AI-based algorithm for stroke prediction
in CKD patients, while widening the application to a larger patient demographic, validating the predictive
algorithm for patients with other chronic diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金